Tagraxofusp for Myelofibrosis: Safety & Early Results

Archyde A new treatment approach for myelofibrosis, tagraxofusp, demonstrates a manageable safety profile and modest clinical activity when used as a single therapy, according to findings from a phase 1/2 clinical… You can read the full story here: Tagraxofusp for Myelofibrosis: Safety & Early Results. Source link

Why Private Varsity Got More Space Than 4 IITs

4 min readNew DelhiUpdated: Feb 20, 2026 01:52 PM IST The Galgotias University incident has put the spotlight on how space was allotted to exhibitors at the global AI event showcasing India’s tech achievements. The exhibition space at the India AI Impact Expo was leased out on a first-come, first-served basis under the supervision of … Read more

Barcelona learn staggering asking price for Julian Alvarez from Atletico Madrid

“Julian is a player under contract with Atletico Madrid and he is happy,” Enrique Cerezo told Egyptian broadcaster Win Win when asked about the links to Catalonia. “No one from Barca has officially contacted us about signing him, and that’s all there is to it.” Diego Simeone has also been vocal in his support of … Read more

Eric Dane, ‘Grey’s Anatomy’ and ‘Euphoria’ Star, Dies at 53

Eric Dane, best known for his role as Dr. Mark Sloan (“McSteamy”) on “Grey’s Anatomy” and as complicated father Cal Jacobs on “Euphoria,” died February 19, his family confirmed to People Magazine. Dane was diagnosed with amyotrophic lateral sclerosis, known as Lou Gehrig’s disease, in 2025. More from Variety “With heavy hearts, we share that Eric … Read more

Earlier SGLT-2 inhibitors for type 2 diabetes could cut deaths, says NICE

image: ©Halfpoint | iStock New guidance from NICE recommends earlier use of SGLT-2 inhibitors and personalised treatment for people with type 2 diabetes, potentially reducing deaths and protecting heart and kidney health while saving the NHS millions According to NICE analysis, the updated recommendations could prevent thousands of deaths over the next few years, improve … Read more